|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||
  Journal of the European Academy of Dermatology and VenereologyVolume 23 Issue 8, Pages 919 - 926 Published Online: 18 May 2009 Journal compilation © 2010 European Academy of Dermatology and Venereology Published on behalf of the European Academy of Dermatology and Venereology
Abstract | References | Full Text: HTML, PDF (Size: 170K) | Related Articles | Citation Tracking  ORIGINAL ARTICLE Quality of life in patients with scalp psoriasis treated with calcipotriol/betamethasone dipropionate scalp formulation: a randomized controlled trial Copyright Journal compilation © 2009 European Academy of Dermatology and Venereology KEYWORDS calcipotriol plus betamethasone dipropionate scalp formulation • quality of life • scalp psoriasis ABSTRACTBackground Psoriasis vulgaris of the scalp has a significant psychosocial impact on individuals affecting their quality of life (QoL). A combination of calcipotriol and betamethasone dipropionate in a formulation suitable for treatment of scalp psoriasis has been developed. Objective To assess the impact of treatment with either calcipotriol plus betamethasone dipropionate scalp formulation or calcipotriol scalp solution on QoL in patients with scalp psoriasis (both within and between treatment groups). Methods This 8-week, randomized, investigator-blind study, compared the once-daily, two-compound scalp formulation (calcipotriol 50 µg/g plus betamethasone 0.5 mg/g as dipropionate; Xamiol Results Treatment with the two-compound scalp formulation (n = 207) resulted in significant improvements from baseline on the SF-36v2 (Physical Component Summary, P = 0.005, week 8; Mental Component Summary, P < 0.05, weeks 2, 4, 8). A significant change from baseline in the calcipotriol scalp solution group (n = 105) was seen only on the Mental Component Summary (P = 0.04, week 8). Change from baseline in Skindex-16 was significantly in favour of the two-compound scalp formulation. Change was significant on both total score and individual scales. Conclusion The two-compound scalp formulation was superior to calcipotriol scalp solution in improving QoL in patients with scalp psoriasis. Conflict of interest declarationJ.P. Ortonne has served as a paid speaker and consultant for LEO Pharma. C. Ganslandt is a salaried employee of LEO Pharma. J. Tan served as a speaker, investigator and advisory board member for LEO Pharma and received honoraria from LEO Pharma for these activities. P. Nordin served as a paid investigator for LEO Pharma in the clinical trial. K. Kragballe has served as a paid speaker and consultant for LEO Pharma. S. Segaert has served as a paid speaker, clinical investigator and consultant for LEO Pharma. Received: 4 July 2008; Accepted 16 January 2009 | 
|
